Impax Laboratories to Present at the Deutsche Bank 35th Annual Health Care Conference

HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will provide an update of their business at the Deutsche Bank 35th Annual Health Care Conference on Wednesday, May 5th, at 9:20 a.m. ET. The conference will be held at the InterContinental Hotel, Boston, MA.

Individuals may listen to the live or an archived presentation made at the conferences, which will be posted in the investor relations section of the Company’s web site at www.impaxlabs.com. This presentation will be archived on the Company’s web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.



CONTACT:

Impax Laboratories, Inc.
Mark Donohue
Sr. Director, Investor Relations and Corporate Communications
(215) 933-3526
www.impaxlabs.com

KEYWORDS:   United States  North America  California  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Ipsen has paused a phase 3 trial of palovarotene after an interim analysis found it is unlikely to meet its primary efficacy endpoint.

Scientists at the Broad Institute and the Dana-Farber Cancer Institute identified 49 existing drugs they believe could be repurposed to treat cancer.

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.